Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am very sorry for your loss. Take care of yourself
INOVIO (Nasdaq: INO) INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
Fri, May 27, 2022, 2:00 PM·6 min read
INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients
INO-5401 + INO-9012 + Libtayo® elicits cancer antigen-specific T cells
55% of MGMT methylated subjects remain alive at a median of 32.5 months
Dr. David Reardon, Principal Investigator, to present on June 6, 2022 at ASCO
PLYMOUTH MEETING, Pa., May 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo® (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), including encouraging median overall survival (OS) data from fifty-two subjects. Median OS duration in unmethylated MGMT (Cohort A) was 17.9 months. Median OS data in MGMT Methylated patients (Cohort B) are being presented for the first time, at a median of 32.5 months, which compares favorably to historical comparisons (23.2-25 months).
Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. The data from this study was selected to be presented in an oral presentation by Dr. David Reardon on Monday, June 6, 2022, at the 2022 American Society of Clinical Oncology (ASCO) at the McCormick Place Convention Center in Chicago, Illinois.
https://finance.yahoo.com/news/inovio-announces-survival-results-ino-120000971.html
INOVIO: Phase II Covid-19 DNA vaccine
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1.full-text
The YouTube video has been deleted! Why? Another red flag?
Nice news for Prana Biotech, I guess
IMHO
XOMA today at the Jefferies Global Healthcare Conference
XOMA is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2014, at 2:00 p.m. ET.
NEWS OUT!!
http://pranabio.com/news/world-leader-movement-disorders-professor-ira-shoulson-joins-prana-board#.U3HhdoF_vSs
World leader in movement disorders Professor Ira Shoulson joins Prana board
MAY 13, 2014
Prana Biotechnology (ASX:PBT) is pleased to announce Professor Ira Shoulson will join the Company’s Board of Directors as a non-Executive Director.
Professor Shoulson is one of the world’s foremost experts in neurodegenerative diseases and movement disorders, and the founder of international academic consortia the Huntington Study Group and Parkinson Study Group, which have been instrumental in the development of innovative drugs to treat these disabling neurological conditions. This is his first company Board position.
Professor Shoulson is Professor of Neurology, Pharmacology and Human Science at Georgetown University, Washington, DC, USA, and Director of the University’s Program for Regulatory Science and Medicine (PRSM). He is also principal investigator of the Georgetown University Center of Excellence in Regulatory Science and Innovation (CERSI), one of four research and education centers currently funded by the Food and Drug Administration (FDA).
Professor Shoulson has served as a consultant to, and member of, several FDA advisory committees over the past three decades, and has been involved in eight successful new drug applications to the FDA, notably long-acting methylphenidate (Concerta©) for attention deficit disorder, rasagiline (Azilect©) for Parkinson disease, and tetrabenazine (Xenazine©), the first drug approved by the FDA for the treatment of chorea in Huntington disease (HD).
Prana Biotechnology CEO and Executive Chairman Geoffrey Kempler said: “Professor Shoulson’s clinical and regulatory experience will be pivotal as Prana prepares to meet with regulators later this year to chart the next steps in PBT2’s development as a treatment for Huntington disease.”
Professor Shoulson said joining the Prana board was an exceptional opportunity to help develop the next generation of treatments for neurodegenerative disorders.
“I have spent my entire professional life developing treatments aimed at making a difference for patients with Huntington disease, Parkinson disease and similar neurodegenerative disorders,” he said.
“Based on the Reach2HD study and ongoing discovery and translational research, I believe PBT2 is among the most promising of experimental treatments intended to ameliorate the disabling cognitive impairment of HD, which is a major source of disability for our patients.”
“Besides PBT2, Prana has an expanding library of compounds that are applicable not just to neurological disorders but other disorders including cancer.”
Professor Shoulson’s position as a non-Executive Director of Prana Biotechnology is effective immediately. Prior to taking up his position with Prana, Professor Shoulson concluded his elected term as Chair and President of the Huntington Study Group.
XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum
XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum
GlobeNewswire XOMA Corporation
1 hour ago
BERKELEY, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that based on its meeting with the U.S Food and Drug Administration (FDA), the Company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. During the meeting, the Company and the FDA reviewed the data generated from XOMA's pilot trial in six PG patients. The pilot study was designed to determine if gevokizumab, an IL-1 beta modulating antibody, should be explored in pivotal studies in patients with active PG. XOMA is incorporating the FDA's verbal and written responses regarding the clinical design of the studies into a final Phase 3 program, which it will submit to the Agency for any final comments.
The Phase 3 program is expected to include two double-blind, placebo-controlled clinical studies, each of which is designed to enroll approximately 60 patients with active PG. The primary endpoint is complete wound closure of the target ulcer at approximately four months. XOMA anticipates conducting these parallel studies in the United States and several other countries.
"The interest we have received from the medical community and the patients who suffer from pyoderma gangrenosum ulcerations reflect their desire to have access to therapeutic options that have been studied specifically in and are approved for this under-served patient population. We were very pleased the FDA agreed PG is a serious rare condition that has been identified as an unmet medical need with no approved therapies and that the input we received has allowed us to design a Phase 3 program we believe we can successfully execute in our targeted PG population," stated Paul Rubin, Senior Vice President, Research and Development and Chief Medical Officer of XOMA. "While we await final comments on our protocol, we are actively engaged in site identification and pre-study start-up activities to ensure their investigators and clinical staff are prepared to enroll eligible patients as quickly as possible once we launch the studies."
Gevokizumab has been granted Orphan Drug Designation by the FDA for the treatment of PG.
About Gevokizumab
Gevokizumab is a potent monoclonal antibody with unique allosteric modulating properties and has the potential to treat patients with a wide variety of inflammatory diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and modulates the cellular signaling events that produce inflammation. IL-1 beta has been shown to be involved in diverse array of disease states, including non-infectious uveitis (including Behcet's uveitis), cardiovascular disease, and other auto-inflammatory diseases.
Gevokizumab currently is being studied in a global Phase 3 clinical program, termed EYEGUARD(TM), which is being conducted by SERVIER and XOMA. This program is designed to determine gevokizumab's ability to treat acute non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye in EYEGUARD-A, to prevent disease flares in patients with Behcet's uveitis in EYEGUARD-B, and to prevent disease flares in NIU patients who are controlled with steroids in EYEGUARD-C.
XOMA has a Proof-of-Concept (POC) program underway in which the Company is exploring the efficacy and safety of gevokizumab in multiple indications. Separately, SERVIER initiated a Phase 2 study to determine gevokizumab's ability to reduce arterial wall inflammation in patients with marked atherosclerotic plaque inflammation and who have experienced an acute coronary syndrome event in the previous twelve months, as well as POC studies in polymyositis/dermatomyositis, giant cell arteritis, and Schnitzler syndrome. Information about gevokizumab clinical studies can be found at www.clinicaltrials.gov and www.clinicaltrialsregister.eu.
About Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. The U.S. Department of Health and Human Services' National Institutes of Health's Office of Rare Disease Research lists PG occurring in about 1 per 100,000 people. Claims data compiled over the past three years indicate the number of diagnosed PG patients has ranged between 11,000 and 14,000 annually. Approximately 50 to 70 percent of the PG patient population has an underlying systemic condition, while the remainder is idiopathic (unknown cause). The most prevalent underlying condition is inflammatory bowel disease (IBD), most commonly ulcerative colitis and Crohn's disease. The prognosis for PG is directly linked to the patient's response to therapy for the underlying disease. Physicians treat patients with systemic therapies that are approved for the underlying disease and topical therapies applied directly to the ulcers; however the ulcers may take up to two years to heal. Despite the ongoing use of systemic therapy, up to 46 percent of patients experience a relapse.
About XOMA Corporation
XOMA has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA's lead product candidate, gevokizumab (IL-1 beta modulating antibody), is in a global Phase 3 program in non-infectious uveitis with its partner SERVIER and multiple proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.
More detailed information can be found at www.xoma.com.
About SERVIER
Founded in 1954, SERVIER is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases, as well as cancer. In 2013, the company recorded a turnover of 4.2 billion euros. 91% of SERVIER drugs are consumed internationally. 27% of turnover from SERVIER drugs were reinvested in Research and Development in 2013. With a strong international presence in 140 countries, SERVIER employs more than 21,000 people worldwide. The SERVIER Group contributed 35% to the 2013 French trade surplus in the pharmaceuticals sector.
http://finance.yahoo.com/news/xoma-finalizes-plans-gevokizumab-phase-130000131.html
CEO Kempler live on autralian TV tonight!!
Update and news expected
http://finance.yahoo.com/mbview/threadview/?&bn=d3a80d22-394e-3b69-81f5-4282c29a0628&tid=1398321064208-c3150694-6b7c-48a3-b6bf-ac45d20b6f43&tls=la%2Cd%2C0%2C3
https://twitter.com/BuchanIR
I guess that the new shares has been naked shorted before being issued.
IMHO
XOMA what's your opinion about XOMA?
Is worth buying here?
TIA
Citron Research is going to issue a new report!!
... and PLUG will tank harder.
IMHO
From the SEC Filing:
Looks like a margin call:
"These sales were required and effected by a financial institution in accordance with the acceleration of repayment obligations pursuant to a loan agreement under which these shares were pledged as collateral".
ALVR is on fire
UP + 115% in Premarket
ALVR is skyrocketing today in Tel-Aviv Stock Exchange!!
Low float stock, will jump higher in Nasdaq today too
Update of the status of the receivership
http://finance.yahoo.com/news/alvarion-receivership-provides-status-receivership-144500718.html
Shareholders meeting has been cancelled
http://www.sec.gov/Archives/edgar/data/1108332/000117184313003136/f6k_080113.htm
Shareholders meeting today
It was scheduled on Thursday, August 1, 2013. Waiting for news.
What's about the Shareholders Meeting?
Anyone knows if has been cancelled?
It was scheduled on Thursday, August 1, 2013. ALVR wants to increase the number of ordinary shares from 12,008,000 ordinary shares to 17,000,000 ordinary shares.
I guess that the new capital raised by the increase of ordinary shares would be very helpful for the company balance sheet.
http://finance.yahoo.com/news/alvarion-announces-annual-general-meeting-120000517.html
Yen Spikes On News Japan Set To Impose New Forex Margin Trading Rules
http://www.zerohedge.com/news/2013-05-30/yen-spikes-news-japan-set-impose-new-forex-margin-trading-rules
New lows is coming, IMHO
I agree with you! Don't touch AONE by now. Wait and see mode is the wise way!!
IMHO
AONE is facing a massive dilution process in the coming weeks! It's a matter of fact.
IMHO
ANTH looking good! $0.76
NVAX - NOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections
ROCKVILLE, Md., March 22, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX - News) announced today that Louis F. Fries III, M.D., its Vice President, Clinical and Medical Affairs, will present results from the company's Phase I clinical trial of its recombinant nanoparticle vaccine candidate against respiratory syncytial virus (RSV) on March 24 and 26, 2012 at the XIV International Symposium on Respiratory Viral Infections in Istanbul, Turkey.
Dr. Fries will discuss results from the blinded, placebo-controlled, escalating-dose trial in separate poster and oral presentations at the conference. In October 2011, Novavax reported interim results from this trial which were consistent with preclinical studies and showed that the vaccine was well-tolerated, highly immunogenic and produced functional antibodies that neutralized RSV.
Dr. Fries stated: "These presentations provide Novavax with the opportunity to report on our Phase I safety and immunogenicity data to an audience of international experts in respiratory viral infections and vaccines. We will discuss the short-term and six month safety of the RSV nanoparticle vaccine in young adults. We will also describe the immunogenicity of our RSV vaccine, as measured by virus neutralization activity, and other immune evaluations that may be associated with protection against RSV. RSV is the most important viral respiratory disease of children globally and a cause of significant morbidity and mortality in the elderly. There is a clear need for an RSV vaccine for these age groups. The data from this trial are very encouraging, and suggest that the RSV nanoparticle vaccine has potential to elicit the level and type of immunity required to protect humans."
Later this year, Novavax expects to initiate two separate dose-ranging Phase II trials of its RSV vaccine candidate in the elderly and in women of child-bearing age. These separate trials will be conducted with, and without, an adjuvant and will provide both safety and immunogenicity results in these different age populations.
About Novavax
Novavax, Inc. (Nasdaq:NVAX - News) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle vaccine technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website: www.novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and its ongoing development of its vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2010, and filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
..Contact:.
.Frederick W. DriscollVP, Chief Financial Officer and Treasurer
Novavax, Inc.240-268-2000....
http://finance.yahoo.com/news/novavax-present-results-phase-rsv-135209180.html
NVAX - NOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine
ROCKVILLE, Md., March 1, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX - News) today announced that it has begun enrollment in a Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate. This randomized, observer-blind, comparator-controlled study is being conducted in multiple centers in Australia under the company's contract with the U.S. Department of Health and Human Services' Office of Biomedical Advanced Research and Development Authority (BARDA) to develop recombinant vaccines for the prevention of seasonal and pandemic influenza. The trial will evaluate the immunogenicity and safety of three dose levels of Novavax's quadrivalent seasonal recombinant VLP influenza vaccine in healthy adults between the ages of 18 and 64.
Stanley C. Erck, President and Chief Executive Officer of Novavax, stated: "The start of this clinical trial is a significant milestone that reflects the progress we have made in our seasonal influenza vaccine program. We believe that most seasonal vaccines in the future will contain a second B strain and thus consist of a quadrivalent, or four-strain, composition. This trial allows us to transition from a trivalent to a quadrivalent seasonal vaccine candidate. The data will help establish the immunogenicity, safety and tolerability of our quadrivalent seasonal influenza VLP vaccine and determine the most effective and appropriate dose for later evaluation in young adults in our upcoming Phase III trial. This trial is being conducted in Australia so that we can evaluate our VLP vaccine candidate prior to the start of the influenza season in the southern hemisphere, and without waiting for the end of influenza transmission in the northern hemisphere. I commend my colleagues and our clinical investigators on their success in launching this important study."
The Phase II trial will enroll up to 500 eligible subjects who will be randomized into five treatment groups of approximately 100 subjects stratified by age and receipt of influenza immunization in the 2011 season. At day zero, study participants will receive a single intramuscular vaccine injection of the quadrivalent vaccine containing one of three ascending doses or one of two trivalent comparators: Novavax vaccine or a standard dose of a licensed trivalent vaccine. Study participants will be evaluated at day 21 for hemagglutination inhibition (HAI) response and safety and tolerability of the vaccine; additional safety and immune response follow-up will continue with the subjects through six months.
Novavax expects to evaluate the top-line data from this Phase II trial in the third quarter of 2012.
About Novavax
Novavax, Inc. (Nasdaq:NVAX - News) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant vaccine nanoparticle (RVN) technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com.
http://finance.yahoo.com/news/novavax-launches-phase-ii-clinical-213000129.html
Broadvision, Jonathan Lebed has been pumping hard BVSN some weeks ago.
Congratulations to the board, great work here!
Actually, THQI had USD 47.7 millions in cash at December 31, 2011
NVAX Publish Results From H1N1 Influenza Vaccine Phase 2 in Mexico
NOVAVAX and the Mexican Social Security Institute Publish Results From H1N1 Influenza Vaccine Trial in Mexico
ROCKVILLE, Md., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX - News) and Specialties Hospital of the National Medical Center, Mexico City, today announced the publication of safety and immunogenicity results from a clinical study of Novavax's A/H1N1 virus-like-particle (VLP) pandemic influenza vaccine candidate in the journal Vaccine. The two-stage, Phase 2, randomized, double-blind, placebo-controlled study was conducted in Mexico during the 2009 pandemic to evaluate the safety and immunogenicity of one or two doses of a monovalent recombinant A/California/04/2009-like influenza VLP vaccine in 4,563 healthy adults, 18-64 years of age.
The study data showed that hemagglutination-inhibiting (HAI) antibody responses to the vaccine fulfilled the immunogenicity criteria that are required to be considered for accelerated approval of seasonal and pandemic influenza vaccines by the US FDA Center for Biologics Evaluation and Research. These criteria were met at all dose levels after a single injection, including the lowest dose of 5 micrograms. Single administrations of the VLP vaccine induced high levels of HAI titers in subjects without pre-existing detectable immunity to the pandemic strain. Overall, the data indicated that Novavax's H1N1 VLP vaccine was well-tolerated and immunogenic.
VLPs mimic the external structure of viruses but lack the genetic material that is responsible for viral replication and infection. Novavax's VLP vaccines are designed to match individual viral strains using proprietary, portable, recombinant cell-culture technology.
The study's principal investigator, Dr. Constantino Lopez-Macias, Professor of Medical Research-Mexican Social Security Institute, stated: "The immune response demonstrated in this study suggests that VLPs can be highly immunogenic and that protective levels of virus-neutralizing immunity can be achieved even with only a 5 microgram dose of the H1N1 VLP vaccine without the use of adjuvants. This is an important advance which we hope will lead to eventual licensure of a VLP vaccine so that we may protect citizens against both seasonal and pandemic influenza viruses."
Dr. Gregory Glenn, Chief Medical Officer of Novavax, stated: "This publication represents the first peer-reviewed publication of clinical data generated using Novavax's influenza VLPs. We demonstrated that our H1N1 influenza VLP vaccine candidate was well-tolerated and generated robust immune responses at antigen doses at or below those administered for egg-derived A/California/04/09 vaccines. This provides important new information supporting our ongoing efforts to develop novel seasonal and pandemic influenza vaccines based on recombinant technology that offers an alternative to eggs and that has potential to be both rapid and cost-effective."
Novavax was awarded an advanced development contract by the Biologics Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services earlier this year. Within the next 12 months, Novavax expects to initiate further clinical evaluations of both seasonal and H5N1 pandemic VLP vaccines under the initial phase of the BARDA contract; a 3 year, $97 million award.
http://finance.yahoo.com/news/NOVAVAX-Mexican-Social-pz-3987292007.html?x=0&.v=1
ARTC bouncing hard
Low floater O/S 25 million shares
XL short covering is coming
Ready to jump
LMRA gaining momo
Ready to jump higher
TARR looking good
TARR looking good!!
TARR running in premarket +16%
Tarragon Corporation Completes Additional $91 Million of Property Sales
Thursday October 18, 5:00 pm ET
NEW YORK, NY--(MARKET WIRE)--Oct 18, 2007 -- Tarragon Corporation (NasdaqGS:TARR - News), a leading mixed use developer with a focus on for rent and for sale multifamily housing, today announced that it has completed the sale of three properties, The Vintage at Abacoa in Jupiter, Florida, 100 East Las Olas in Ft. Lauderdale, Florida and the Kennesaw Farms Apartments development in Gallatin, Tennessee for a total of $91,367,000.
William Friedman, Tarragon's Chairman and Chief Executive Officer, said, "While our recent sales have been motivated by the need to reduce debt and increase liquidity in the face of very difficult market conditions, we realized a pretax profit of over $20 million on the sale of The Vintage at Abacoa which we built in 2003, making up for some of the losses on recent transactions. I am pleased to also announce that we have fully implemented agreements announced earlier this month with several of our lenders to reinstate over $150 million of loans previously in default."
TARR running in premarket +16%
Tarragon Corporation Completes Additional $91 Million of Property Sales
Thursday October 18, 5:00 pm ET
NEW YORK, NY--(MARKET WIRE)--Oct 18, 2007 -- Tarragon Corporation (NasdaqGS:TARR - News), a leading mixed use developer with a focus on for rent and for sale multifamily housing, today announced that it has completed the sale of three properties, The Vintage at Abacoa in Jupiter, Florida, 100 East Las Olas in Ft. Lauderdale, Florida and the Kennesaw Farms Apartments development in Gallatin, Tennessee for a total of $91,367,000.
William Friedman, Tarragon's Chairman and Chief Executive Officer, said, "While our recent sales have been motivated by the need to reduce debt and increase liquidity in the face of very difficult market conditions, we realized a pretax profit of over $20 million on the sale of The Vintage at Abacoa which we built in 2003, making up for some of the losses on recent transactions. I am pleased to also announce that we have fully implemented agreements announced earlier this month with several of our lenders to reinstate over $150 million of loans previously in default."
UBET jumping!! $ 1.83
OS 42.2 millions
http://stockcharts.com/h-sc/ui?s=UBET&p=D&yr=0&mn=6&dy=0&id=p42261134619
UBET is jumping $1.79
OS 42.2 million
http://stockcharts.com/h-sc/ui?s=UBET&p=D&yr=0&mn=6&dy=0&id=p42261134619
UBET looking good, ready to move